



Divi's Laboratories Limited

Date: May 20, 2023

To
The Secretary
National Stock Exchange of India Limited
Exchange Plaza,
Bandra-Kurla Complex, Bandra (East)
MUMBAI – 400 051

Stock Code: DIVISLAB

To
The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street
MUMBAI – 400 001

Stock Code: 532488

Dear Sir / Madam,

Sub: Outcome of Board Meeting held on May 20, 2023

Ref: Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015

Further to our letter dated May 12, 2023, we would like to inform that the Board of Directors of the Company at its meeting held on May 20, 2023 has:

- a) Approved the Audited Financial Results (Standalone and Consolidated) for the quarter and year ended March 31, 2023.
- b) Recommended a Dividend of ₹ 30/- (i.e. 1,500%) per equity share of face value ₹ 2/- each for the financial year 2022-23, subject to approval of the members at the ensuing 33rd Annual General Meeting (AGM). The dividend shall be credited / warrants thereof dispatched within specified timelines from the conclusion of the AGM. The AGM date and record date for the purpose of the payment of dividend will be announced in due course.

Financial Results

In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we are enclosing herewith the following:

1. Statement of Audited Standalone Financial Results for the quarter and year ended March 31, 2023 and Auditors' Report thereon.
2. Statement of Audited Consolidated Financial Results for the quarter and year ended March 31, 2023 and Auditors' Report thereon.
3. Declaration regarding Audit Reports with unmodified opinion.



Divi's Laboratories Limited

The Board meeting commenced at 10:40 Hrs and concluded at 13.10 Hrs.

This is for your information and records.

Thanking You,
Yours faithfully,
For Divi's Laboratories Limited

M. Satish Choudhury
Company Secretary & Compliance Officer

DIVI'S LABORATORIES LIMITED
STATEMENT OF STANDALONE AUDITED FINANCIAL RESULTS
FOR THE QUARTER AND YEAR ENDED MARCH 31, 2023

(₹ in lakhs)

S. No.	Particulars	Quarter ended			Year ended	
		31.03.2023	31.12.2022	31.03.2022	31.03.2023	31.03.2022
		(Audited) *	(Unaudited)	(Audited) *	(Audited)	(Audited)
1	Income:					
	Revenue from operations	190817	168983	249503	762530	887982
	Other Income	6615	11634	5051	34901	11126
	Total Income	197432	180617	254554	797431	899108
2	Expenses					
	a) Cost of materials consumed	79265	59660	92843	297949	343979
	b) Purchases of stock-in-trade	-	-	-	-	-
	c) Changes in inventories of finished goods work-in-progress and stock-in-trade	2273	15115	(5953)	5016	(44999)
	d) Employee benefits expense	25194	23284	25149	95305	92655
	e) Depreciation and amortisation expense	8663	8654	8075	34207	31055
	f) Finance costs	18	11	4	52	65
	g) Other expenses	35215	29982	27867	129492	108701
	Total expenses	150628	136706	147985	562021	531456
3	Profit before exceptional Items and tax (1-2)	46804	43911	106569	235410	367652
4	Exceptional items	-	-	-	-	-
5	Profit before Tax (3-4)	46804	43911	106569	235410	367652
6	Tax expense					
	a) Current tax	10551	10458	14469	43758	63720
	b) Deferred tax	4374	2363	3804	10837	9078
	Total tax expense	14925	12821	18273	54595	72798
7	Profit for the Period/Year (5-6)	31879	31090	88296	180815	294854
8	Other Comprehensive Income:					
	Items that will not be reclassified to Profit or Loss:					
	(i) Gain on Remeasurement of post-employment benefit obligation	107	84	317	359	335
	(ii) Income tax relating to the above	(71)	(18)	(112)	(126)	(117)
	Total other comprehensive Income (i+ii)	36	66	205	233	218
9	Total comprehensive Income for the period/year (7+8)	31915	31156	88501	181048	295072
10	Paid-up Equity Share Capital (Face Value: Rs. 2/- per share)	5309	5309	5309	5309	5309
11	Other Equity excluding revaluation reserve				1265233	1163826
12	Earnings per Share of Rs. 2/- each (not annualized)					
	a) Basic (Rs.)	12.01	11.71	33.26	68.11	111.07
	b) Diluted (Rs.)	12.01	11.71	33.26	68.11	111.07



DIVI'S LABORATORIES LIMITED

STANDALONE AUDITED STATEMENT OF ASSETS AND LIABILITIES

(₹ in lakhs)

	Particulars	As At	
		31.03.2023	31.03.2022
		Audited	Audited
A	ASSETS		
1	Non-current assets		
	Property, plant and equipment	471348	431348
	Capital work-in-progress	21188	46993
	Intangible assets	528	749
	Financial assets		
	a) Investments	8441	7937
	b) Other financial assets	5095	5763
	Income tax assets (net)	2917	2917
	Other non-current assets	2100	5483
	Sub-total: Non-current assets	511617	501190
2	Current assets		
	Inventories	278045	264405
	Financial assets		
	a) Trade receivables	196430	256990
	b) Cash and cash equivalents	14417	119956
	c) Bank balances other than (b) above	404339	160412
	d) Other financial assets	607	484
	Income tax assets (net)	9787	5768
	Other current assets	19920	21581
	Sub-total: Current assets	923545	829596
	TOTAL ASSETS	1435162	1330786
B	EQUITY AND LIABILITIES		
1	Equity:		
	Share Capital	5309	5309
	Other Equity	1265233	1163826
	Sub-total: Shareholders' funds	1270542	1169135
2	Liabilities:		
	Non-current liabilities		
	Provisions	3062	2671
	Deferred tax liabilities (net)	53721	42140
	Sub-total: Non-current liabilities	56783	44811
3	Current Liabilities		
	Financial liabilities		
	a) Borrowings	-	-
	b) Trade payables:		
	Dues to micro and small enterprises	3749	2478
	Dues to Creditors other than micro and small enterprises	70515	74652
	c) Other financial liabilities	4339	6289
	Other current liabilities	28742	33006
	Provisions	492	415
	Sub-total: Current liabilities	107837	116840
	Total Liabilities	164620	161651
	TOTAL EQUITY AND LIABILITIES	1435162	1330786



DIVI'S LABORATORIES LIMITED
STANDALONE AUDITED STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED MARCH 31, 2023

(₹ in Lakhs)

Particulars	For the year ended	
	31.03.2023 (Audited)	31.03.2022 (Audited)
A. Cash flow from operating activities		
Profit before income tax	235410	367652
Adjustments for:		
Depreciation and amortisation expense	34207	31055
Unrealised foreign exchange gain	(1551)	(567)
Interest income from financial assets at amortised cost	(20459)	(6896)
Change in fair value of investment in optionally convertible debentures	(504)	-
Provision for doubtful debts / (written back) [including bad debts recovered]	-	(277)
Interest expense	18	21
Loss on disposal / discard of property, plant and equipment and intangible assets	113	205
Amortisation of government grants	(10)	(9)
	247224	391184
Change in operating assets and liabilities		
(Increase) /Decrease in trade receivables	63807	(81710)
(Increase) /Decrease in inventories	(13640)	(60135)
Increase /(Decrease) in trade payables	(2953)	2429
(Increase) /Decrease in other non-current assets	450	125
(Increase) /Decrease in other current financial assets	(123)	463
(Increase) /Decrease in other non-current financial assets	668	(93)
(Increase) /Decrease in other current assets	1661	(6451)
Increase /(Decrease) in long term employee benefit obligation	750	481
Increase /(Decrease) in short term employee benefit obligation	77	164
Increase/ (Decrease) in other financial liabilities	(83)	502
Increase /(Decrease) in other current liabilities	(5884)	7036
Cash generated from operations	291954	253995
Income taxes paid including withholding tax and net of refunds	(47159)	(62979)
Net cash inflow from operating activities	244795	191016
B. Cash flows from investing activities		
Payments for property, plant and equipment	(47215)	(71368)
Proceeds from sale of property, plant and equipment	1	-
Payment for Investments in optionally convertible debentures	-	(7200)
Interest received	20459	6681
Proceeds from withdrawal of deposits	160118	5050
Investment in deposits	(404038)	(152703)
Net cash inflow / (outflow) from investing activities	(270675)	(219540)



DIVI'S LABORATORIES LIMITED

**STATEMENT OF STANDALONE AUDITED CASH FLOWS
FOR THE YEAR ENDED MARCH 31, 2023 (contd..)**

(₹ In lakhs)

Particulars	31.03.2023 (Audited)	31.03.2022 (Audited)
C. Cash flows from financing activities		
Proceeds/ (Repayment) of working capital loans (net)	-	(35)
Interest paid	(18)	(21)
Dividends paid to company's shareholders	(79641)	(53094)
Net cash inflow / (outflow) from financing activities	(79659)	(53150)
Net increase / (Decrease) in cash and cash equivalents (A+B+C)	(105539)	(81674)
Cash and cash equivalents at the beginning of the financial year	119956	201630
Cash and cash equivalents at end of the year	14417	119956

NOTES:

- The above Statement of standalone audited financial results for the quarter and year ended March 31, 2023, Standalone audited statement of assets and liabilities and Standalone audited statement of cash flows as at and for the year ended March 31, 2023 ('Standalone Statements') are prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The same were, as reviewed by the Audit Committee, considered and approved by the Board of Directors at its meeting held on May 20, 2023. The same also were audited by the Auditors of the Company and their report contains no qualification.
- The Company is engaged in the manufacture of Active Pharmaceutical Ingredients, intermediates and nutraceutical ingredients; and the same constitutes a single reportable business segment as per Ind AS 108.
- The Company does not have any discontinued operations and the Profit for the year represents the Profits from continuing operations only.
- *Figures for the quarter ended 31.03.2023 and corresponding quarter ended 31.03.2022 are the balancing figures between audited figures in respect of the full financial year and the unaudited published year-to-date figures up to the third quarter of the respective financial years.
- The Board of Directors of the company has recommended a dividend of ₹30/- per share of face value ₹ 2/- each i.e., 1500% for the financial year 2022-23, subject to approval of members at the ensuing annual general meeting.


6. Details of forex gain/loss are given below:

(₹ in lakhs)

	Quarter ended			Year Ended	
	31.03.2023	31.12.2022	31.03.2022	31.03.2023	31.03.2022
	(Audited)*	(Unaudited)	(Audited)*	(Audited)	(Audited)
Forex gain/ (loss)	(272)	4874	2929	13402	3798

Forex gain has been included in Other Income and loss has been included in Other Expenses.

For Divi's Laboratories Limited


Dr. Murali K. Divi
Managing Director

Place: Hyderabad
Date: May 20, 2023



Price Waterhouse Chartered Accountants LLP

Independent Auditor's Report

To the Board of Directors
Divi's Laboratories Limited
Divi's Towers, 1-72/23/(P)/Divis/303,
Cyber Hills, Gachibowli
Hyderabad-500032

Report on the Audit of Standalone Financial Results

Opinion

1. We have audited the statement of standalone audited financial results of Divi's Laboratories Limited (hereinafter referred to as the "Company") for the year ended March 31, 2023 and the standalone audited statement of assets and liabilities as at March 31, 2023 and the standalone audited statement of cash flows for the year ended March 31, 2023, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ('Listing Regulations') which has been initialled by us for identification purposes.
2. In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial results:
 - (i) are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
 - (ii) give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 (the "Act") and other accounting principles generally accepted in India, of net profit and other comprehensive income and other financial information of the Company for the year ended March 31, 2023 and the standalone statement of assets and liabilities and the standalone statement of cash flows as at and for the year ended on that date.

Basis for Opinion

3. We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act and other applicable authoritative pronouncements issued by the Institute of Chartered Accountants of India. Our responsibilities under those Standards are further described in the 'Auditor's Responsibilities for the Audit of the Standalone Financial Results' section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.



Price Waterhouse Chartered Accountants LLP, Unit - 2B, 8th Floor, Octave Block, Block E1, Parcel - 4, Salarpuria
Satva Knowledge City, Raidurg, Hyderabad, Telangana - 500081
T: +91 (40) 4424 6000, F: +91 (40) 4424 6300

Registered office and Head office: 11-A, Vishnu Digamber Marg, Sucheta Bhawan, Gate No 2, 1st Floor, New Delhi - 110002

Price Waterhouse (a Partnership Firm) converted into Price Waterhouse Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-5001) with effect from July 25, 2014. Post its conversion to Price Waterhouse Chartered Accountants LLP, its ICAI registration number is 012754N/N500016 (ICAI registration number before conversion was 012754N)

Price Waterhouse Chartered Accountants LLP

Independent Auditor's Report
To the Board of Directors of Divi's Laboratories Limited
Report on the Standalone Financial Results
Page [2] of [3]

Board of Directors' Responsibilities for the Standalone Financial Results

4. These Standalone financial results have been prepared on the basis of the standalone annual financial statements. The Company's Board of Directors are responsible for the preparation and presentation of these standalone financial results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Company and the standalone statement of assets and liabilities and the standalone statement of cash flows in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Board of Directors of the Company are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the standalone financial results by the Directors of the Company, as aforesaid.
5. In preparing the standalone financial results, the Board of Directors of the Company are responsible for assessing the ability of the Company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.
6. The Board of Directors of the Company are responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

7. Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.
8. As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
 - Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
 - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal



Price Waterhouse Chartered Accountants LLP

Independent Auditor's Report
To the Board of Directors of Divi's Laboratories Limited
Report on the Standalone Financial Results
Page [3] of [3]


financial controls with reference to standalone financial statements in place and the operating effectiveness of such controls. (Refer paragraph 11 below)

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
 - Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
 - Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the standalone financial results represent the underlying transactions and events in a manner that achieves fair presentation.
9. We communicate with those charged with governance of the Company regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

10. The standalone financial results include the results for the quarter ended March 31, 2023 being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year, which are neither subject to limited review nor audited by us.
11. The standalone annual financial results dealt with by this report has been prepared for the express purpose of filing with stock exchange on which company's shares are listed. These results are based on and should be read with the audited standalone financial statements of the Company for the year ended March 31, 2023 on which we issued an unmodified audit opinion vide our report dated May 20, 2023.

For Price Waterhouse Chartered Accountants LLP
Firm Registration Number: 012754N/N500016



Varadarajan N.K

Partner

Membership Number: 090196

UDIN: 23090196 BGIYZIS1897


Place: Hyderabad
Date: May 20, 2023

DIVI'S LABORATORIES LIMITED


STATEMENT OF CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2023

(₹ in lakhs)

S. No	Particulars	Quarter ended			Year ended	
		31.03.2023	31.12.2022	31.03.2022	31.03.2023	31.03.2022
		(Audited)*	(Unaudited)	(Audited)*	(Audited)	(Audited)
1	Income:					
	Revenue from operations	195077	170768	251844	776751	895983
	Other Income	6615	11425	5239	34466	11387
	Total Income	201692	182193	257083	811217	907370
2	Expenses					
	a) Cost of materials consumed	80840	60440	91460	300836	347656
	b) Purchases of stock-in-trade	-	1237	501	2233	1441
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	1918	12278	(8099)	2303	(52383)
	d) Employee benefits expense	25764	23888	25676	97502	94616
	e) Depreciation and amortisation expense	8702	8677	8099	34318	31151
	f) Finance costs	24	13	8	67	80
	g) Other expenses	37796	32097	31864	137095	116459
	Total expenses	155044	138630	149509	574354	539020
3	Profit before exceptional Items and tax (1-2)	46648	43563	107574	236863	368350
4	Exceptional items	-	-	-	-	-
5	Profit before Tax (3-4)	46648	43563	107574	236863	368350
6	Tax expense					
	a) Current tax	10221	10663	14545	43917	64400
	b) Deferred tax	4330	2220	3565	10608	7905
	Total tax expense	14551	12883	18110	54525	72305
7	Profit for the period/year (5-6)	32097	30680	89464	182338	296045
8	Profit for the period/ year attributable to:					
	Shareholders of the Company	32097	30680	89464	182338	296045
	Non-Controlling Interest	-	-	-	-	-
9	Other Comprehensive Income:					
	a) Items that will not be reclassified to Profit or Loss:					
	i) Gain on Remeasurement of post-employment benefit obligations	107	84	317	359	335
	ii) Income tax relating to the above	(71)	(18)	(112)	(126)	(117)
	b) Items that will be reclassified to Profit or Loss:					
	i) Gain/(Loss) on exchange differences in translating the financial statements of a foreign operation	87	353	(53)	1179	233
	ii) Income tax relating to the above	(8)	(70)	(9)	(218)	(45)
10	Total Other comprehensive Income (a+b)	115	349	143	1194	406
	Total other comprehensive income for the year/period attributable to:					
	Shareholders of the Company	115	349	143	1194	406
	Non-Controlling Interest	-	-	-	-	-
11	Total comprehensive Income for the period/year (7+9)	32212	31029	89607	183532	296451
12	Total comprehensive income for the period/ year attributable to:					
	Shareholders of the Company	32212	31029	89607	183532	296451
	Non-Controlling Interest	-	-	-	-	-
13	Paid-up Equity Share Capital	5309	5309	5309	5309	5309



(Signature)



	(Face Value: Rs 2/- per share)					
14	Other equity excluding revaluation reserve				1271400	1167509
15	Earnings per Share of Rs 2/- each (not annualized)					
	a) Basic (Rs)	12.09	11.56	33.70	68.69	111.52
	b) Diluted (Rs)	12.09	11.56	33.70	68.69	111.52



(Handwritten signature)



DIVI'S LABORATORIES LIMITED

CONSOLIDATED AUDITED STATEMENT OF ASSETS AND LIABILITIES

(₹ in lakhs)

	Particulars	As At	
		31.03.2023	31.03.2022
		Audited	Audited
A	ASSETS		
I	Non-current assets		
	Property, plant and equipment	471417	431412
	Right to use assets	315	344
	Capital work-in-progress	21188	46993
	Intangible assets	528	749
	Financial assets		
	a) Investments	7705	7201
	b) Other financial assets	5109	5775
	Income tax assets(net)	2917	2917
	Deferred tax asset	1424	1447
	Other non-current assets	2100	5483
	Sub-total: Non-current assets	512703	502321
2	Current assets		
	Inventories	300041	282862
	Financial assets		
	a) Trade receivables	179253	242388
	b) Cash and cash equivalents	16970	121476
	c) Bank balances other than (b) above	404339	160412
	d) Other financial assets	607	489
	Income-tax asset (net)	9787	5768
	Other current assets	20177	21755
	Sub-total: Current assets	931174	835150
	TOTAL ASSETS	1443877	1337471
B	EQUITY AND LIABILITIES		
I	Equity:		
	Share Capital	5309	5309
	Other Equity	1271400	1167509
	Sub-total: Shareholders' funds	1276709	1172818
2	Liabilities:		
	Non-current liabilities		
	Financial liabilities		
	a) Lease liabilities	277	287
	Provisions	3062	2671
	Deferred tax liabilities (net)	53721	42140
	Sub-total: Non-current liabilities	57060	45098
3	Current Liabilities		
	Financial liabilities		
	a) Borrowings	-	-
	b) Lease liabilities	49	82
	c) Trade payables:		
	Dues to micro and small enterprises	3749	2478
	Dues to Creditors other than micro and small enterprises	72502	77092
	d) Other financial liabilities	4339	6289
	Current tax liabilities (net)	221	168
	Other current liabilities	28756	33031
	Provisions	492	415
	Sub-total: Current liabilities	110108	119555
	Total Liabilities	167168	164653
	TOTAL EQUITY AND LIABILITIES	1443877	1337471




DIVI'S LABORATORIES LIMITED
CONSOLIDATED AUDITED STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED MARCH 31, 2023

(₹ in lakhs)

Particulars	For the year ended	
	31.03.2023 (Audited)	31.03.2022 (Audited)
A. Cash flow from operating activities		
Profit before tax	236863	368350
Adjustments for:		
Depreciation and amortisation expense	34318	31151
Unrealised foreign exchange loss/ (gain)	(209)	(544)
Exchange differences on translation of foreign operations	1179	233
Interest income from financial assets at amortised cost	(20459)	(6896)
Change in fair value of investments in optionally convertible debentures	(504)	-
Provision for doubtful debts / (written back) [including bad debts recovered]	33	(203)
Interest expense	33	36
Loss on disposal / discard of property, plant and equipment and intangible assets	113	205
Amortisation of government grants	(10)	(9)
	251357	392323
Change in operating assets and liabilities		
(Increase) /Decrease in trade receivables	65041	(74162)
(Increase) /Decrease in inventories	(17179)	(68339)
Increase /(Decrease) in trade payables	(3406)	3427
(Increase) /Decrease in other non-current assets	450	125
(Increase) /Decrease in other non-current financial assets	666	(88)
(Increase) /Decrease in other current financial assets	(118)	458
(Increase) /Decrease in other current assets	1578	(6436)
Increase /(Decrease) in long term employee benefit obligation	750	481
Increase /(Decrease) in short term employee benefit obligation	77	164
Increase/ (Decrease) in other financial liabilities	(83)	284
Increase /(Decrease) in other current liabilities	(5895)	7041
Cash generated from operations	293238	255278
Income taxes paid including withholding tax and net of refunds	(47265)	(64098)
Net cash inflow from operating activities	245973	191180
B. Cash flows from investing activities		
Payments for property, plant and equipment	(47302)	(71320)
Proceeds from sale of property, plant and equipment	1	-
Payments for Investments in Optionally Convertible Debentures	-	(7200)
Interest received	20459	6681
Proceeds from withdrawal of deposits	160118	5050
Investment in deposits	(404038)	(152703)
Net cash inflow / (outflow) from investing activities	(270762)	(219492)



(Handwritten Signature)



DIVI'S LABORATORIES LIMITED
CONSOLIDATED AUDITED STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED MARCH 31, 2023 (contd..)

(₹ in lakhs)

Particulars	31.03.2023 (Audited)	31.03.2022 (Audited)
C. Cash flows from financing activities		
Proceeds/ (repayment) of working capital loans	-	(35)
Interest paid	(33)	(36)
Principal elements of lease liabilities paid	(43)	(79)
Dividends paid to company's shareholders	(79641)	(53094)
Net cash inflow / (outflow) from financing activities	(79717)	(53244)
Net increase / (Decrease) in cash and cash equivalents (A+B+C)	(104506)	(81556)
Cash and cash equivalents at the beginning of the financial year	121476	203032
Cash and cash equivalents at end of the year	16970	121476

NOTES:


- The above Statement of consolidated audited financial results for the quarter and year ended March 31, 2023, Consolidated audited statement of assets and liabilities and Consolidated audited statement of cash flows as at and for the year then ended March 31, 2023 ('Consolidated Statements') are prepared in accordance with Indian Accounting Standards ('IndAS') prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The same were, as reviewed by the Audit Committee, considered and approved by the Board of Directors at its meeting held on May 20, 2023. The same also were audited by the Auditors of the Company and their report contains no qualification.
- The consolidated results include the audited financial results of the wholly owned subsidiaries Divis Laboratories (USA) Inc and Divi's Laboratories Europe AG.
- The Group is engaged in the manufacture of Active Pharmaceutical Ingredients, intermediates and nutraceutical ingredients; and the same constitutes a single reportable business segment as per Ind AS 108.
- The Group does not have any discontinued operations and the Profit for the year represents the Profits from continuing operations only.
- *Figures for the quarter ended 31.03.2023 and corresponding quarter ended 31.03.2022 are the balancing figures between audited figures in respect of the full financial year and the unaudited published year-to-date figures up to the third quarter of the respective financial years.
- The Board of Directors of the Company has recommended a dividend of ₹30/- per share of face value ₹ 2/- each i.e., 1500% for the financial year 2022-23, subject to approval of members at the ensuing annual general meeting.
- Details of forex gain/(loss) are as given below:

(₹ in lakhs)


	Quarter ended			Year Ended	
	31.03.2023 (Audited)*	31.12.2022 (Unaudited)	31.03.2022 (Audited)*	31.03.2023 (Audited)	31.03.2022 (Audited)
Forex gain/ (loss)	(421)	4665	3116	12967	4058

Forex gain has been included in Other Income and loss has been included in Other Expenses.

For Divi's Laboratories Limited


Dr. Murali K. Divi
Managing Director

Place: Hyderabad
Date: May 20, 2023



Price Waterhouse Chartered Accountants LLP

Independent Auditor's Report

To
The Board of Directors
Divi's laboratories Limited
Divi's Towers, 1-72/23/(P)/Divis/303,
Cyber Hills, Gachibowli
Hyderabad-500032

Report on the Audit of Consolidated Financial Results

Opinion

1. We have audited the Statement of consolidated audited financial results of Divi's Laboratories Limited (hereinafter referred to as the 'Holding Company') and its subsidiaries (Holding Company and its subsidiaries together referred to as "the Group") (Refer note 2 to the consolidated annual financial results) for the year ended March 31, 2023, Consolidated audited statement of assets and liabilities as at March 31, 2023 and the Consolidated audited statement of cash flows for the year ended March 31, 2023, attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations') which has been initialled by us for identification purposes.
2. In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of reports of other auditors on separate audited financial statements of the subsidiaries, the aforesaid consolidated financial results:
 - (i) include the annual financial results of the following entities: Divi's Laboratories Limited, Divis Laboratories (USA) Inc., and Divi's Laboratories Europe AG;
 - (ii) are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
 - (iii) give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 (the "Act") and other accounting principles generally accepted in India, of net profit and other comprehensive income and other financial information of the Group for the year ended March 31, 2023 and the consolidated statement of assets and liabilities and the consolidated statement of cash flows as at and for the year ended on that date.

Basis for Opinion

3. We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act and other applicable authoritative pronouncements issued by the Institute of Chartered Accountants of India. Our responsibilities under those Standards are further described in the 'Auditor's Responsibilities for the Audit of the Consolidated Financial Results' section of our report. We are independent of the Group, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in "Other Matter" paragraph below, is sufficient and appropriate to provide a basis for our opinion.



Price Waterhouse Chartered Accountants LLP, Unit - 2B, 8th Floor, Octave Block, Block E1, Parcel - 4, Salarpuria
Sattva Knowledge City, Raidurg, Hyderabad, Telangana - 500081
T: +91 (40) 4424 6000, F: +91 (40) 4424 6300

Registered office and Head office: 11-A, Vishnu Digamber Marg, Sucheta Bhawan, Gate No 2, 1st Floor, New Delhi - 110002

Price Waterhouse (a Partnership Firm) converted into Price Waterhouse Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-5001) with effect from July 25, 2014. Post its conversion to Price Waterhouse Chartered Accountants LLP, its ICAI registration number is 012754N/N500016 (ICAI registration number before conversion was 012754N)

Price Waterhouse Chartered Accountants LLP

Independent Auditor's Report
To the Board of Directors of Divi's Laboratories Limited
Report on the Consolidated Financial Results
Page [2] of [4]

Board of Directors' Responsibilities for the Consolidated Financial Results

4. These Consolidated financial results have been prepared on the basis of the consolidated annual financial statements. The Holding Company's Board of Directors are responsible for the preparation and presentation of these consolidated financial results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Group, the consolidated statement of assets and liabilities and the consolidated statement of cash flows in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial results by the Directors of the Holding Company, as aforesaid.
5. In preparing the consolidated financial results, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.
6. The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

7. Our objectives are to obtain reasonable assurance about whether the consolidated financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial results.
8. As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
 - Identify and assess the risks of material misstatement of the consolidated financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
 - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the holding company has adequate internal financial controls



Price Waterhouse Chartered Accountants LLP


Independent Auditor's Report
To the Board of Directors of Divi's Laboratories Limited
Report on the Consolidated Financial Results
Page [3] of [4]

with reference to consolidated financial statements in place and the operating effectiveness of such controls. (Refer paragraph 13 below)

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
 - Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
 - Evaluate the overall presentation, structure and content of the consolidated financial results, including the disclosures, and whether the consolidated financial results represent the underlying transactions and events in a manner that achieves fair presentation.
 - Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Group to express an opinion on the consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated financial results of which we are the independent auditors. For the other entities included in the consolidated financial results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.
9. We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.
10. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

Other Matters

11. We did not audit the financial statements of two subsidiaries included in the consolidated financial results, whose financial statements reflect total assets of Rs. 43,224 Lakhs and net assets of Rs. 10,371 Lakhs as at March 31, 2023, total revenues of Rs. 51,538 Lakhs and Rs. 12,725 Lakhs, total net profit after tax of Rs. 2,699 Lakhs and Rs. 505 Lakhs and total comprehensive income of Rs. 3,403 Lakhs and Rs. 433 Lakhs for the year ended March 31, 2023 and for the period from January 01, 2023 to March 31, 2023 respectively, and net cash inflows of Rs.1,033 Lakhs for the year ended on March 31, 2023, as considered in the consolidated financial results have been prepared in accordance with accounting principles generally accepted in their respective countries and have been audited by other auditors under generally accepted auditing standards applicable in their respective countries. The Holding Company's management has converted the financial statements of such subsidiaries located outside India from the accounting principles generally accepted in their respective countries to the accounting policies generally accepted in India. We have audited these conversion adjustments made by the Holding Company's management and our opinion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based on the reports of the other auditors and



Price Waterhouse Chartered Accountants LLP


Independent Auditor's Report
To the Board of Directors of Divi's Laboratories Limited
Report on the Consolidated Financial Results
Page [4] of [4]

the conversion adjustments prepared by the management of the Holding Company and audited by us and the procedures performed by us as stated in paragraph 10 above.

Our opinion on the consolidated Financial Results is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors.

12. The Consolidated Financial Results include the results for the quarter ended March 31, 2023 being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year, which are neither subject to limited review nor audited by us.
13. The consolidated annual financial results dealt with by this report have been prepared for the express purpose of filing with stock exchanges on which the Holding Company's shares are listed. These results are based on and should be read with the audited consolidated financial statements of the group for the year ended March 31, 2023 on which we have issued an unmodified audit opinion vide our report dated May 20, 2023.

For Price Waterhouse Chartered Accountants LLP
Firm Registration Number: 012754N/N500016



Varadarajan N.K
Partner

Membership Number: 090196
UDIN: 2309019636YZIT1047

Place: Hyderabad
Date: May 20, 2023



Divi's Laboratories Limited

Date: May 20, 2023

To
The Secretary
National Stock Exchange of India Limited
Exchange Plaza,
Bandra-Kurla Complex, Bandra (East)
MUMBAI – 400 051

To
The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street
MUMBAI – 400 001

Stock Code: DIVISLAB

Stock Code: 532488

Dear Sir/Madam,

Sub: Declaration regarding Audit Reports with unmodified opinion

Ref: Regulation 33(3)(d) of SEBI (LODR) Regulations, 2015

With reference to the above, we hereby declare that the Statutory Auditors of the Company, have issued Audit Reports with Unmodified Opinion on the Audited Standalone and Consolidated Financial results for the year ended March 31, 2023.

This is for your information and records.

Thanking You,

Yours faithfully,
For Divi's Laboratories Limited

L. Kishore Babu
Chief Financial Officer

